ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In the 2022 updates, the ELTS score, along with TKI resistance, additional cytogenetic abnormalities, and ABL1 kinase mutations, are now considered when diagnosing high-risk CP- or AP-CML (Table 1).